Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Ref. No: ADL/2-L/2014
Date : 8th August, 2014

To, Listing/Compliance Department BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. **BSE CODE: 524348**	To, Listing/Compliance Department The National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. **NSE SYMBOL: AARTIDRUGS**

Dear Sirs,

Ref.: Compliance of Clause 41 of the Listing Agreement.
Sub: Audited Financial Results for the quarter ended 30th June, 2014.

In terms of Clause 41 of the Listing Agreement, we are forwarding herewith the Audited Financial Results along with Auditor's Report on Financial Results of the Company for the quarter ended 30th June, 2014 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on Friday 8th august, 2014 at Mumbai.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspapers as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**

SUNNY PAGARE
COMPANY SECRETARY
Encl: as above.

CIN NO : L37060MH1984PLC055433

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE , 2014

(Rs in Lacs except for share data)

PART I						
			Quarter Ended			Financial Year Ended
Sr. No.	Particulars		30th June 2014 (Audited)	31st March 2014 (Audited)	30th June 2013 (Audited)	31st March 2014 (Audited)
1	**Income from Operations**					
	(a) Gross Sales / Income from Operations		27,877	30,386	23,527	104,435
	Less : Excise Duty & Sales Tax		1,917	2,207	1,668	7,441
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)		25,960	28,179	21,859	96,994
	(b) Other Operating Income		10	125	5	183
	Total Income from operations (net)		25,970	28,304	21,865	97,176
2	**Expenditure**					
	(a) Cost of materials consumed		16,709	15,867	13,088	57,082
	(b) Purchase of stock-in-trade		3,195	1,756	2,483	8,602
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		(2,052)	2,383	(577)	569
	(d) Employee benefits expense		872	862	740	3,241
	(e) Depreciation and Amortisation Expense		741	759	669	2,812
	(f) Other expenses		3,261	3,366	3,030	13,046
	Total expenses		22,725	24,793	19,433	85,351
3	**Profit from Operations before Other Income, finance costs and exceptional items**	(1-2)	3,245	3,511	2,432	11,825
4	Other Income		3,245	3,511	2,432	11,825
5	**Profit from ordinary activities before finance cost and exceptional items**	(3+4)	982	917	728	3,349
6	Finance costs (interest)		2,262	2,595	1,704	8,476
7	**Profit from ordinary activities after finance cost but before Exceptional Items**	(5-6)	-	-	-	-
8	Exceptional Items		2,262	2,595	1,704	8,476
9	**Profit from Ordinary Activities before Tax**	(7-8)				
10	**Tax Expenses**		539	399	520	2,397
	Provision for Taxation - Current		480	630	440	2,300
	- MAT Credit Entitlment		(21)	-	-	-
	- Earlier year		-	(321)	-	(253)
	Provision for Deferred Taxation		80	90	80	350
11	**Net profit from ordinary Activities after Tax**	(9-10)	1,724	2,195	1,184	6,080
12	Extraordinary items		-	-	-	92
13	**Net Profit for the Period (11+12)**		1,724	2,195	1,184	6,171
14	Paid-up Equity Share Capital of Rs.10/- each.		1,211	1,211	1,211	1,211
15	Reserves & Surplus (excluding revaluation reserves)					23,880
16	**Earning per share (of Rs. 10 /- each) (not annualised)**					
	(a) Basic & Diluted (before extraordinary items)		14.24	18.13	9.78	50.21
	(b) Basic & Diluted (after extraordinary items)		14.24	18.13	9.78	50.97

For AARTI DRUGS LTD.

R. Managing Director

CIN NO : L...

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

PART II

A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	-Number of Shares	4,852,768	4,890,428	5,044,266	4,890,428
	-Percentage of Total Shareholding	40.08	40.39	41.86	40.39
2	Promoters & Promoter Group shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil
	b) Non-encumbered				
	- Number of Shares	7,255,782	7,218,122	7,064,284	7,218,122
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100	100	100	100
	-Percentage of shares(as a % of the total Share capital of the company)	59.92	59.61	58.34	59.61

		Qtr Ended 30th June' 2014
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresloved at the end of the quarter	0

Notes:

1 The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 8th August, 2014

2 Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.

3 Figures for the previous period have been regrouped or rearranged wherever necessary.

4 The estimated useful lives of fixed assets have been reviewed and revised to align with the provisions of PART C of Schedule II to the Companies Act 2013, effective from April 1, 2014.

For and on behalf of the Board
For AARTI DRUGS LIMITED

HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)
DIN:- 00005340

Place :Mumbai
Date: 08/08/2014

gokhale & sathe
(regd.)
chartered accountants
308/309, udyog mandir no. 1,
7-c, bhagoji keer marg,
mahim, mumbai 400 016

Auditor's Report on Quarterly Financial Results and Year to Date Results of AARTI DRUGS LTD Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of AARTI DRUGS LTD

We have audited the quarterly financial results of AARTI DRUGS LTD for the quarter ended 30th June 2014, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 on Interim Financial Reporting issued under the Companies (Accounting Standard Rules), 2006 which continue to apply under section 133 of the Companies Act 2013 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

GOKHALE & SATHE ★ MUMBAI ★ CHARTERED ACCOUNTANTS ★ FIRM No. 103264W

tel.: (22) 43 48 42 42 | fax : (22) 43 48 42 41 | office@gokhalesathe.in

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

(i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the quarter ended 30th June 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No: 103264W

GOKHALE & SATHE ★ CHARTERED ACCOUNTANTS ★ MUMBAI FIRM No. 103264W

CA. TEJAS J. PARIKH
PARTNER
Membership No. 123215
Mumbai, Dated: August 8th, 2014